Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05799066 · ClinicalTrials.gov registry record · NA
Measuring Relative Afferent Pupillary Defect
A NA study of Relative Afferent Pupil Defect (RAPD), sponsored by The University of Texas Medical Branch, Galveston.
- Active
- Registry status
- NA
- Development phase
- 71
- Enrollment target
- 1
- Study location
NCT05799066: Active NA study of Relative Afferent Pupil Defect (RAPD), sponsored by The University of Texas Medical Branch, Galveston.
NCT05799066 is a NA study of Relative Afferent Pupil Defect (RAPD) that is active but no longer recruiting, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 71 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05799066, a NA study of Relative Afferent Pupil Defect (RAPD), is active but no longer recruiting, sponsored by The University of Texas Medical Branch, Galveston.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 71 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this prospective reliability study is to test the effectiveness of a commercially available, off-the-shelf virtual reality head-mounted display (VR HMD) and machine learning (ML) algorithms in detecting Relative Afferent Pupillary Defect (RAPD) in a group of subjects with known RAPD and another group with no known RAPD. The main questions it aims to answer are: * Does the use of the VR HMD and ML to replace the standard of care swinging flashlight test provide a more reliable and objective pupil measurement to detect RAPD? * Can RAPD be detected by the VR HMD and ML algorithms at an earlier stage than the standard of care swinging light test? Participants will be asked to undergo the standard of care swinging flashlight test, have their pupils manually measured, then have the test repeated using the VR HMD and ML. Researchers will compare the measurements taken manually, following the standard of care swinging light test and those recorded by the VR HMD and ML to help answer the above questions.
Primary Outcome
Measure of pupil size in each eye, measured manually or via machine learning algorithms
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Swinging Light test
- DIAGNOSTIC_TEST Virtual Reality Head-Mounted Display (VR HMD)
Study Locations (1)
Texas
- University of Texas Medical Branch - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2023-05-04 |
| Est. Completion | 2026-05-14 |
| Phase | NA |
What the registry record for NCT05799066 still lists
NCT05799066 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Relative Afferent Pupil Defect (RAPD) appearing as the primary indexed condition, and to 2 interventions - of which Swinging Light test is the first listed.
NCT05799066 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05799066 about?
NCT05799066 is a clinical study titled "Measuring Relative Afferent Pupillary Defect". The goal of this prospective reliability study is to test the effectiveness of a commercially available, off-the-shelf virtual reality head-mounted display (VR HMD) and machine learning (ML) algorithms in detecting Relative Afferent Pupillary Defect (RAPD) in a group of subjects with known RAPD and ...
What is the current status of trial NCT05799066?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 71 participants. The study started on 2023-05-04. Estimated completion is 2026-05-14.
What conditions does trial NCT05799066 study?
This clinical trial studies the following conditions: Relative Afferent Pupil Defect (RAPD).
What interventions are being tested in trial NCT05799066?
The interventions under investigation include: Swinging Light test (DIAGNOSTIC_TEST), Virtual Reality Head-Mounted Display (VR HMD) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05799066?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05799066 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05799066's enrollment target sits among peer trials
71 1102nd of 2000 higher than 898 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI